Brief: GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results
GT Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: GT Biopharma Reports Q1 2021 Results
Brief: Gt Biopharma Announces Gtb-3550 Trike Monotherapy Rescues And Restores Nk Cell Immune Surveillance In Relapsed/Refractory Aml And Mds Cancer Patients
GT Biopharma: Up on prelim data from cancer drug study
Brief: Gt Biopharma Adds University Of Wisconsin--Madison Carbone Cancer Center As Second Site In Ongoing Phase 1/2 Clinical Trial Of Gtb-3550 Trike
Brief: GT Biopharma Transfers Trike Manufacturing To Cytovance Biologics
Brief: GT Biopharma Announces Closing Of $23.7 Mln Public Offering
U.S. STOCKS ON THE MOVE-Shutterstock, Tilray, Zillow, Cancer Genetics, Spirit Airlines
U.S. STOCKS ON THE MOVE-Zynga, Kraft Heinz, Molson Coors, Hexo, Cancer Genetics
U.S. STOCKS ON THE MOVE-Shutterstock, Tilray, Tyson Foods, Crypto stocks
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
Brief: Gt Biopharma Says Have Applied To List Our Common Stock On Nasdaq Capital Market Under Symbol “GTBP.”
Brief: Gt Biopharma Submits Application For Uplisting To The Nasdaq Capital Market
Brief: Gt Biopharma Intends To Apply To List Common Stock On The Nasdaq Capital Market Under The Symbol “GTBP”
Brief: GT Biopharma Announces Sale Of Its Fixed Dose Combination Tablet (Gtb-004) For Myasthenia Gravis (Chronic Autoimmune Disease) To Das Therapeutics
Brief: Gt Biopharma Gtb-1550 Clinical Development Update
Brief: GT Biopharma Receives Institutional Review Board Approval To Proceed With In Human FDA Phase 1 Clinical Trial
Brief: GT Biopharma Names Anthony J Cataldo As Chief Executive Officer